Invitrogen™ Vulinacimab Recombinant Monoclonal Antibody

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Vulinacimab, also known as HLX-06, is a monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR-2). VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) is a critical gene located on chromosome 4q12, encoding a receptor tyrosine kinase involved in vascular development and angiogenesis. The receptor structure encompasses seven immunoglobulin-like domains in the extracellular region, a single transmembrane helix, and an intracellular tyrosine kinase domain. Upon binding to VEGF ligands, VEGFR2 undergoes dimerization and autophosphorylation, activating downstream signaling pathways such as the PI3K-Akt, MAPK, and PLC gamma cascades. These pathways regulate endothelial cell proliferation, migration, survival, and permeability, playing a vital role in physiological processes like wound healing and pathological conditions such as cancer and diabetic retinopathy. Therapeutically, targeting VEGFR2 has shown efficacy in various cancers due to its central role in tumor angiogenesis.